Top

International Journal of Colorectal Disease

Published in:

01-06-2009 | Original Article

Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone

Authors: Oliver Nehls, Holger G. Hass, Thomas Okech, Silke Zenner, Chih-Jen Hsieh, Mario Sarbia, Franz Borchard, Hans-Helmut Gruenagel, Vera Gaco, Rainer Porschen, Michael Gregor, Bodo Klump

Published in: International Journal of Colorectal Disease | Issue 6/2009

Abstract

Purpose

This study examined whether the apoptosis-related protein, BAX, or the microsatellite-instability phenotype provide prognostic information in patients with resected colon cancer.

Methods

A total of 371 stage I–III patients that previously underwent radical surgery were included (mean follow-up 51.8 months). BAX expression was examined by immunohistochemical staining; high-frequency microsatellite instability (MSI+) was determined by assessing the specific marker, BAT26, using single-strand conformation polymorphism (SSCP)-based analysis.

Results

High BAX expression was found in 66.4% of patients. MSI+ tumors were observed in 14.8% of 344 patients. Univariate analysis showed that unlike MSI, low BAX expression was significantly correlated with poor disease-specific overall survival (OS) in stages I–III (p = 0.04). Multivariate subgroup analyses revealed that unlike MSI, low BAX was an independent predictor for OS in stage II (p = 0.009); however, in stages I or III, BAX or MSI were not independent predictors of OS.

Conclusions

In stage II colon cancer treated with surgery alone, BAX protein expression may be a predictor for prognosis.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics 2007. CA Cancer J Clin 57:43–66PubMedCrossRef

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, shepherd LE, Seitz JF, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806PubMedCrossRef

Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ (2007) Adjuvant treatment for colorectal cancer. CA Cancer J Clin 57:168–185PubMedCrossRef

Lindmark G, Bergström R, Pahlmann L, Glimelius B (1995) The association of preoperative serum tumor markers with Duke’s stage and survival in colorectal cancer. Br J Cancer 71:1090–1094PubMed

Greene FL, Stewart AK, Norton J (2002) A new TNM staging strategy for node positive (stage III) colon cancer. Ann Surg 4:416–421CrossRef

Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767PubMedCrossRef

Perucho M (1996) Cancer of the microsatellite mutator phenotype. Biol Chem 377:675–684PubMed

Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609–618PubMedCrossRef

Kerr J, Wyllie A, Currie A (1972) Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26:239–257PubMed

10.

Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299PubMedCrossRef

11.

Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R (1997) BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 57:300–303PubMed

12.

Loukola A, Eklin K, Laiho P, Solovaara R, Kristo P, Järvinen H, Mecklin JP, Launonen V, Aaltonen LA (2001) Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 61:4545–4549PubMed

13.

Jansson A, Sun XF (2002) BAX expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol 20:811–816PubMedCrossRef

14.

Söreide K, Janssen EAM, Söiland H, Körner H, Baak JPA (2006) Microsatellite instability in colorectal cancer. Br J Surgery 93:395–406CrossRef

15.

Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dorken P, Daniel PT (1999) Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17:1364–1374PubMed

16.

Schelwies K, Sturm I, Grabowski P, Scherubl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dorken P, Daniel PT (2002) Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumours. Int J Cancer 99:589–596PubMedCrossRef

17.

Nehls O, Okech T, Hsieh CJ, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Porschen R, Gregor M, Klump B (2005) Low BAX protein expression correlates with disease-recurrence in preoperatively irradiated rectal carcinoma. Int J Radiat Oncol Biol Phys 61:85–91PubMed

18.

Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Hass HG, Arkenau HAT, Hartmann JT, Porschen R, Gregor M, Klump B (2007) Studies on p53, BAX, and Bcl-2 protein expression in stage III (UICC) colon cancer treated by adjuvant chemotherapy: Major prognostic impact of proapoptotic BAX pronounced by intact p53. Br J Cancer 96:1409–1418PubMed

19.

Sobin LH, Wittekind C (1997) TNM Classification of Malignant Tumours. UICC, International Union against cancer, 5th edn. Wiley-Liss, New York

20.

Giatromanolaki A, Sivridis E, Stathopoulos GP, Fountzilas G, Kalofonos HP, Tsamandas A, Vrettou E, Scopa C, Polychronidis A, Simopoulos K, Koukourakis MI (2001) Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse. Anticancer Res 21:253–259PubMed

21.

Koda M, Reszec J, Sulkowska M, Kanczuga-Koda L, Sulkowski S (2004) Expression of the insulin-like growth factor-I receptor and proapoptotic BAX and Bak proteins in human colorectal cancer. Ann N Y Acad Sci 1030:377–383PubMedCrossRef

22.

Backus HHJ, van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM, Peters GJ (2004) Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol 55:206–211

23.

Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B (2001) P53 alterations and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7:1343–1349PubMed

24.

Evertson S, Wallin A, Arbman G, Rütten S, Emterling A, Zhang H, Sun XF (2003) Microsatellite instability and MBD4 mutation in unselected colorectal cancer. Anticancer Res 23:3569–3574PubMed

25.

Wang C, van Rijnsoever M, Grieu F, Bydder S, Elsaleh H, Joseph D, Harvey J, Iacopetta B (2003) Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology 64:259–265PubMedCrossRef

26.

Minamoto T, Esumi H, Ochiai A, Belitsky G, Mai M, Sugimura T, Ronai Z (1997) Combined analysis of microsatellite instability and k-ras mutation increases detection of normal samples from colorectal cancer patients. Clin Cancer Res 3:1413–1417PubMed

27.

Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. New Engl J Med 342:69–77PubMedCrossRef

28.

Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S (2003) Tumor microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New Engl J Med 349:247–257PubMedCrossRef

29.

Nakata B, Muguruma K, Hirakawa K, Chung YS, Yamashita Y, Inoue T, Matsuoka T, Onoda N, Kato Y, Sowa M (1998) Predictive value of Bcl-2 and BAX protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology 55:543–547PubMedCrossRef

30.

Kang SY, Han JH, Lee KJ, Choi J-H, Park JI, Kim HI, Lee H-W, Jang JH, Park JS, Kim HC, Kang S, Oh YT, Chun M, Kim JH, Sheen SS, Lim H-Y (2007) Low expression of BAX predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res 13:4146–4153PubMedCrossRef

31.

Theodorakis P, Lomonosova E, Chinnadurai G (2002) Critical requirement of BAX manifestation of apoptosis induced by multiple stimuli in human epithelial cancer cell lines. Cancer Res 62:3373–3376PubMed

32.

Schrag D, Cramer LD, Bach PB, Cohen AM, Warren JL, Begg CB (2000) Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 284:3028–3035PubMedCrossRef

33.

Rabeneck L, Davila JA, Thompson M, El-Serag HB (2004) Surgical volume and long-term survival following surgery for colorectal cancer in the Veterans Affairs Health-Care System. Am J Gastroenterol 99:668–675PubMedCrossRef

Title: Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone
Authors: Oliver Nehls
Holger G. Hass
Thomas Okech
Silke Zenner
Chih-Jen Hsieh
Mario Sarbia
Franz Borchard
Hans-Helmut Gruenagel
Vera Gaco
Rainer Porschen
Michael Gregor
Bodo Klump
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 6/2009
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-009-0635-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2009

Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment

Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma

Mitochondrial D-loop mutation is a common event in colorectal cancers with p53 mutations

‘Flatus tube enema’ as an alternative to flexible sigmoidoscopy in reducing colonic volvulus and pseudo-obstruction: letter

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer